In another study in vitro, the antileukemic effects of seven metabolic inhibitors on patient-derived AML cells were compared, targeting various metabolic pathways, including glycolysis (among these, the selective MCT1 inhibitor AZD3965), the pentose phosphate pathway, glutaminolysis, and fatty acid oxidation. Here, SLC16A1 is linked to acute myeloid leukemia.